GVK BIO, a leading Contract Research & Development (R&D) Organization that services the global Biopharma industry; is headquartered in Hyderabad, India with operations in seven sites including California, USA. Established in 2001, GVK BIO has over 19 years of rich experience across the Research and Development value chain with a focus on speed and quality. Our team of over 2500 highly qualified scientists, backed by well-defined and scalable processes, modern facilities and a strong customer-centric partnering approach, focus on bringing our customers’ products to market.
Location: India, Telangana, Hyderabad
Employees: 1001-5000
Founded date: 2001
Investors 1
| Date | Name | Website |
| 13.05.2024 | ChrysCapit... | chryscapit... |
Mentions in press and media 3
| Date | Title | Description |
| 19.04.2021 | BCS-based Biowaiver – Alternative to Human Bioequivalence Studies, Upcoming Webinar Hosted by Xtalks | On a conservative basis, it is estimated to save ~ 120 – 140 million in dollars in clinical study costs per year through granting BCS based bio waivers for Class I and Class III drugs. TORONTO (PRWEB) April 19, 2021 Biopharmaceutics classif... |
| 02.12.2015 | India: PE firm ChrysCapital to buy Sequoia’s 10% stake in GVK Bio for $25m | Premium Private equity firm ChrysCapital is buying a 10% stake in Hyderabad-based contract research company GVK Biosciences for about $25 million, as per a report in The Times of India. Continue reading this story with a subscription to Dea... |
| 26.11.2007 | Life sciences briefing: Monday, Nov. 26, 2007 | Featured companies: Biospace Med, Carbylan BioSurgery, GVK BioSciences, IntraSafe Medical, InViragen, Medingo, ParadigmHealth, Precimed, SV Life Sciences UPDATED: Expanded items on Carbylan, Medingo, and GVK Biosciences. Carbylan raises $20... |